- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07620587
The Role of Estradiol and Progesterone on Appetite Regulation and Energy Balance (E2 & P4 in EB)
Studieoversigt
Status
Detaljeret beskrivelse
The purpose of this study is to further elucidate the individual and combined effects of estradiol and progesterone on appetite-regulating hormones, perceptions of appetite, energy intake, and energy expenditure over a 13 day supplementation period using a randomized controlled trial (RCT) model in males who will be supplemented with each hormone. Sixty healthy, recreationally active male participants will be randomized into one of four possible groups: placebo (PLA; 400 milligrams (mg) per day glucose polymer), estradiol only (E; 1 mg per day for 2 days & 2 mg per day of estradiol for 11 days + 300 mg Polycose), progesterone only (P; Prometrium, 100 mg per day), or combined estradiol and progesterone (E+P; 1 mg per day for 2 days & 2 mg per day of estradiol for 11 days + 300 mg Polycose for estradiol and 100 mg per day of Prometrium) for a total of ~15 per group. Participants will be provided enough daily dose of each treatment dependent on randomization for a total of 13 days and will be instructed to take each supplement orally at the same time each day for the entirety of the intervention. Participants will report to the lab on the 7th day, where they will be fed a standardized meal and then complete either an acute bout of high-intensity interval training (HIIT; 1 minute on, 1 minute off at 90% HRmax) or a period of seated rest (CTRL). Participants will return on day 12 to complete either the HIIT or CTRL session in an identical manner (whichever was not completed on day 7). Blood samples to measure appetite-regulating hormones and perceptions of appetite will be completed pre-exercise, 0-, 30-, 60-, and 120-minutes post-HIIT and CTRL. While participants are receiving the 13 day treatment, free-living energy intake will be assessed for a 3 day period (day before, day of and day after both in lab visits (HIIT/CTRL; days 6-8 and days 11-13) using the Keenoa® mobile application, and energy expenditure will be measured via thigh-worn accelerometers for the same 3 day periods. An ad libitum meal will also be provided following the HIIT and CTRL sessions.
We anticipate publishing this RCT in two separate manuscripts. Manuscript #1 will focus on the potential effects on the appetite-regulating hormones (acylated ghrelin, GLP-1, CCK) and perceptions of appetite. Manuscript #2 will focus on potential effects on energy balance from the measures of energy intake (including free-living and ad-libitum meal intake) and energy expenditure.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Jessica Tucker, MKin, PhD Candidate
- Telefonnummer: 4919 519-884-1970
- E-mail: tuck5010@mylaurier.ca
Studiesteder
-
-
Ontario
-
Waterloo, Ontario, Canada, N2L 3C5
- Rekruttering
- Energy Metabolism Research Laboratory
-
Kontakt:
- Jessica Tucker, MKin, PhD Candidate
- Telefonnummer: 4919 519-884-1970
- E-mail: tuck5010@mylaurier.ca
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- ages 18-30 years
- deemed healthy using Canadian Society for Exercise Physiology Get Active Questionnaire (CSEP-GAQ)
- non-smoking
Exclusion Criteria:
- failure to meet inclusion criteria
contraindications to exercise as indicated by the (CSEP-GAQ)
- hypersensitivity or allergy to estradiol, progesterone, cellulose, or capsule components
- having been diagnosed with any metabolic disease (ie. diabetes, metabolic syndrome) or current diagnosis of overweight/obesity (BMI > 30.0)
- personal of family history of stroke or thrombotic (blood clot) disease, blood clot disorder, venous or arterial thromboembolic disease, or any possible blood clotting disease
- currently taking anticoagulants, antidiabetic medications, cyclosporine, antihypertensives, and CYP3A4 inducers or inhibitors (e.g., rifampin, ketoconazole, St. John's Wort)
- known liver dysfunction or liver disease
- history of ophthalmic vascular disease
- hormone-dependent malignancies or previous diagnosis of cancer
- recent major surgery (within ~6 months)
- prolonged use of a cast or presence of immobility deeming inability to exercise, diagnosis of inflammatory disorders (ie. rheumatoid arthritis, celiac disease, inflammatory bowel disease)
- history of sensitivity to or extreme nausea/vomiting or any gastrointestinal disorder
- diagnosis of mental health or mood disorder
- presence of abnormal eating behaviours as assessed by the Food Cravings State Questionnaire and the Three Factor Eating Questionnaire
- diagnosed or presence of porphyria or classical migraines
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo Comparator
Participants will be randomized and placed into one of four groups.
The placebo group will receive 400 milligrams (mg) per day of glucose polymer for 13 days total.
The supplementation will be consumed orally at the same time every day for 13 days total.
Participants will not complete more than one arm of the study.
|
See description of intervention arm.
|
|
Eksperimentel: Estradiol Only
Participants will receive 1 mg per day for 2 days and 2 mg per day of estradiol for 11 days + 300 mg polycose.
The supplementation will be consumed orally at the same time every day for 13 days total.
Participants will not complete more than one arm of the study.
|
See description of intervention arm.
|
|
Eksperimentel: Progesterone Only
Participants will receive 100 mg per day of Prometrium (oral progesterone) for 13 days.
The supplementation will be consumed orally at the same time every day for 13 days total.
Participants will not complete more than one arm of the study.
|
See description of intervention arm.
|
|
Eksperimentel: Estradiol and Progesterone Combo
Participants will receive 1 mg per day for 2 days and 2 mg per day estradiolfor 11 days + 300 mg polycose as well as 100 mg per day of Prometrium (oral progesterone).
The supplementation will be consumed orally at the same time every day for 13 days total.
Participants will not complete more than one arm of the study.
|
See description of intervention arm.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Energy balance
Tidsramme: Energy balance will be measured using the data collected surrounding the exercise and no-exercise sessions (6 days total).
|
Energy balance will be calculated as the difference between energy intake and energy expenditure (see below for description of energy intake and energy expenditure).
|
Energy balance will be measured using the data collected surrounding the exercise and no-exercise sessions (6 days total).
|
|
Acylated Ghrelin
Tidsramme: To be measured pre-exercise, 0 minutes post-exercise, 30 minutes post-exercise, 60 minutes post-exercise, and 120 minutes post-exercise.
|
Appetite-stimulating hormone acylated ghrelin to be measured via commercially available ELISA kits (pg/mL).
|
To be measured pre-exercise, 0 minutes post-exercise, 30 minutes post-exercise, 60 minutes post-exercise, and 120 minutes post-exercise.
|
|
Glucagon-like Peptide 1 (GLP-1)
Tidsramme: To be measured pre-exercise, 0 minutes post-exercise, 30 minutes post-exercise, 60 minutes post-exercise, and 120 minutes post-exercise.
|
Appetite-inhibiting hormone GLP-1 to be measured via commercially available ELISA kits (pmol/L).
|
To be measured pre-exercise, 0 minutes post-exercise, 30 minutes post-exercise, 60 minutes post-exercise, and 120 minutes post-exercise.
|
|
Cholecystokinin (CCK)
Tidsramme: To be measured pre-exercise, 0 minutes post-exercise, 30 minutes post-exercise, 60 minutes post-exercise, and 120 minutes post-exercise.
|
Appetite-inhibiting hormone CCK to be measured via commercially available ELISA kits (pg/ml).
|
To be measured pre-exercise, 0 minutes post-exercise, 30 minutes post-exercise, 60 minutes post-exercise, and 120 minutes post-exercise.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Appetite perceptions
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Subjective appetite perceptions will be assessed using visual analogue scales (VAS) validated for four perceptions: hunger (i.e., "How hungry do you feel?"), satisfaction (i.e., "How satisfied do you feel?"), fullness (i.e., "How full do you feel?"), and prospective food consumption (i.e., "How much do you think you can eat?").
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Food Preferences
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
For food preferences, a state food preference questionnaire is a survey or questionnaire used to gather information about individuals' food preferences, and dietary habits.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Ad libitum meal energy intake
Tidsramme: At the end of each in-lab session (exercise and seated rest; 2 meals total).
|
A post in-lab session meal will be provided to all participants to determine their ad libitum energy intake for this meal by measuring the food provided before the meal as well as the amount of food not consumed using an analog scale .
|
At the end of each in-lab session (exercise and seated rest; 2 meals total).
|
|
Free-living energy intake
Tidsramme: Day before, day of, and day after each in-lab session (6 days total).
|
Participants will complete a 3 day food record around each in lab session using a mobile application (Keenoa®) monitored by a registered dietician.
|
Day before, day of, and day after each in-lab session (6 days total).
|
|
Energy expenditure
Tidsramme: Day before, day of, and day after each in-lab session (6 days total).
|
Energy expenditure will be measured for the same 3 days of the food records around both in-lab sessions measured using a thigh-worn accelerometer.
|
Day before, day of, and day after each in-lab session (6 days total).
|
|
Estradiol
Tidsramme: Pre-exercise only.
|
Sex hormone estradiol measured via radioimmunoassay (pg/mL).
|
Pre-exercise only.
|
|
Progesterone
Tidsramme: Pre-exercise only.
|
Sex hormone progesterone measured via radioimmunoassay (ng/mL).
|
Pre-exercise only.
|
|
Testosterone
Tidsramme: Pre-exercise only.
|
Sex hormone testosterone measured via radioimmunoassay.
|
Pre-exercise only.
|
|
Blood glucose
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Will be measured using biochemical assays prior to and following treatment.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Insulin
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Will be measured using biochemical assays prior to and following treatment.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
C-Peptide
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Will be measured using biochemical assays prior to and following treatment.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Peripheral Blood Mononuclear Cells
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured by flow cytometry and biochemical assays/arrays both before and after treatment and before and after an acute bout of exercise.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Inflammatory Cytokines
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured by flow cytometry and biochemical assays/arrays both before and after treatment and before and after an acute bout of exercise.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Brain-derived Neurotrophic Factor (BDNF)
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via ELISA kits.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Cathepsin B
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via ELISA kits.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Irisin
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via ELISA kits.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Klotho
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via ELISA kits.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Adrenocorticotropic Hormone
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Dickkopf-1 (DKK-1)
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Fibroblast Growth Factor 23 (FGF-23)
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Interleukin 1B (IL-1B)
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Interleukin-6 (IL-6)
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Tumor Necrosis Factor (TNF)
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Osteocalcin
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Osteopontin
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Osteoprotegerin (OPG)
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Parathyroid Hormone (PTH)
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Sclerostin
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
|
Leptin
Tidsramme: Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Measured in blood samples via immunoassays.
|
Pre-exercise/seated rest as well as 0 minutes, 30 minutes, 60 minutes and 120 minutes following exercise/seated rest.
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Tom J Hazell, PhD, Wilfrid Laurier University
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- EMRL-25-01
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Energibalance
-
University of ReadingBiotechnology and Biological Sciences Research Council; The Norwegian Institute... og andre samarbejdspartnereAfsluttetProtein-Energy UnderernæringDet Forenede Kongerige
-
Hospital General Universitario Gregorio MarañonInstituto de Salud Carlos III; European Regional Development Fund; Maternal...UkendtProtein-Energy UnderernæringSpanien
-
Assistance Publique - Hôpitaux de ParisAfsluttetProtein-Energy UnderernæringFrankrig
-
Maastricht University Medical CenterIkke rekrutterer endnuProtein-Energy Underernæring | Dårlig ernæringHolland
-
Mairaj NoorAfsluttetFejlernæring (kalorie) | Protein-energi fejlernæringPakistan
-
An Hsin QingShui ClinicAfsluttet
-
Seoul St. Mary's HospitalAfsluttetProtein-Energy UnderernæringKorea, Republikken
-
Semarang Health PolytechnicUkendtAnæmi | Graviditet | Protein-Energy UnderernæringIndonesien
-
University of FloridaAfsluttetNyresvigt | Protein-Energy UnderernæringForenede Stater
-
VU University of AmsterdamAmsterdam UMC, location VUmc; University of HelsinkiAfsluttetFysisk handicap | Protein-Energy UnderernæringFinland, Holland
Kliniske forsøg med Placebo Comparator
-
Merck Sharp & Dohme LLCAfsluttetHIV-1 infektion
-
CHIA-HUI MAMackay Memorial HospitalAfsluttet
-
Atea Pharmaceuticals, Inc.AfsluttetSund frivillig undersøgelseCanada
-
Asahi Kasei Pharma America CorporationTrukket tilbage
-
National University of SingaporeRekrutteringMild kognitiv svækkelseSingapore
-
The Center for Clinical and Cosmetic ResearchBirchBioMed Inc.AfsluttetCicatrix | Ar | Keloid | Hypertrofisk arForenede Stater
-
Moberg Pharma ABAktiv, ikke rekrutterendeOnykomykoseForenede Stater, Canada
-
Medical University InnsbruckBarmherzige Brüder Vienna; Tiroler Landeskrankenanstalten GmbH (TILAK); Tiroler... og andre samarbejdspartnereAfsluttetSlag | Iskæmisk angreb, forbigående | Cost benefit analyse | Sekundær forebyggelse | SygdomshåndteringØstrig
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetRace/etniske minoriteter på dialyseForenede Stater
-
Hospital Clinic of BarcelonaRekrutteringRygestop | Tobaksbrugsforstyrrelse | Psykisk lidelseSpanien